|Bid||4.01 x 0|
|Ask||4.01 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|Beta (3Y Monthly)||4.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) applauds the United Kingdom’s decision to allow specialist doctors the option to legally issue prescriptions for cannabis-based medicines when they believe patients could benefit from the treatment. The law change, passed in Parliament yesterday, came after Home Secretary Sajid Javid listened to concerns from parents of children with conditions such as severe epilepsy.
Chris, Formerly with Incredibles, One of the Industry’s Leading Vape, Extracts and Wellness Companies, Has Nearly Two Decades of Experience in Greenhouse Architecture, Management and Cultivation. TORONTO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced the Florida Department of Health, Office of Medical Marijuana Use (“DOH”) has approved the transfer of 60% of the Equity of 3 Boys Farms, LLC. (“3 Boys Farms”) to CannCure Investments Inc. (“CannCure”) including 3 Boys Farms’ license to operate as a Medical Marijuana Treatment Center in Florida.
Scythian Biosciences Corp. (“Scythian” or the “Company”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) announced its intention to commence a normal course issuer bid (“NCIB”), under which the Company may purchase up to 2,451,861 of the Company’s common shares, representing approximately 5% of its issued and outstanding common shares (the “Shares”). The Company is commencing the NCIB because it believes that, from time to time, the market price of its Shares may not fully reflect the underlying value of the Company’s business and future prospects.
Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) announces that it has entered into a definitive share purchase agreement (the “Purchase Agreement”) with MMJ International Investments Inc. (“MMJ”), a privately-held British Columbia company and all of the shareholders of MMJ, to acquire all of the issued and outstanding common shares of MMJ (the “Acquisition”). MMJ is the owner of Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina. ABP also holds a license to import cannabidiol oil into Argentina. The Purchase Agreement supersedes the previously-announced business combination agreement between Scythian and MMJ to effect the Acquisition.
Closing Is Key Benchmark in Finalizing Previously Announced $193 Million Sale of Assets in Caribbean and Latin America. Shares to Be Received in Consideration for the Proposed Sale of Assets in Caribbean ...
TORONTO, Aug. 27, 2018-- Scythian Biosciences Corp. has completed its acquisition of MMJ Colombia Partners Inc., a privately-held Ontario company that owns 90% of Colcanna SAS, a company that cultivates, ...